Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
暂无分享,去创建一个
Andres Forero | James N. Ingle | Vered Stearns | Lisa A. Carey | Steven J. Isakoff | C. Hudis | Minetta C. Liu | L. Carey | K. Blackwell | H. Rugo | J. Ingle | T. Traina | A. Doane | M. Danso | V. Stearns | A. Forero | M. Moynahan | S. Isakoff | D. Giri | L. Nabell | S. Tolaney | S. Patil | Dilip D. Giri | Hope Rugo | Clifford A. Hudis | Sujata Patil | Lisle Nabell | Ayca Gucalp | Kimberly Blackwell | Mary Ellen Moynahan | A. Gucalp | Tiffany A. Traina | Sara Tolaney | Ashley S. Doane | Michael Danso | Lamia F. Momen | Joseph M. Gonzalez | Arooj Akhtar | Kimberly N. Feigin | K. Feigin | A. Akhtar | L. Momen | Joseph Gonzalez
[1] E. Eisenhauer,et al. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study , 1988, Investigational New Drugs.
[2] R. Tamimi,et al. Androgen Receptor Expression in Breast Cancer in Relation to Molecular Phenotype: Results from the Nurses’ Health Study , 2011, Modern Pathology.
[3] W. Gerald,et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.
[4] G. Morgante,et al. Hormonal effects of flutamide in young women with polycystic ovary syndrome. , 1998, The Journal of clinical endocrinology and metabolism.
[5] Harvard Medical School,et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. , 2011, Cancer cell.
[6] Ji Liu,et al. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. , 2010, Cancer letters.
[7] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[8] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[9] Vittorio Cristini,et al. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family , 2009, BMC Medical Genomics.
[10] Carsten Denkert,et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy , 2011, Breast Cancer Research and Treatment.
[11] H. Park,et al. Expression of androgen receptors in primary breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A. Ravaud,et al. Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis , 2007, Cancer.
[13] M. Bahçeci,et al. Serum C-Reactive Protein (CRP) Levels and Insulin Resistance in Non-Obese Women with Polycystic Ovarian Syndrome, and Effect of Bicalutamide on Hirsutism, CRP Levels and Insulin Resistance , 2004, Hormone Research in Paediatrics.
[14] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[15] Anastasia Ivanova,et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Güven,et al. New alternative treatment in hirsutism: bicalutamide 25 mg/day , 2002, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[17] W. Gerald,et al. Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.
[18] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[19] Luke Hughes-Davies,et al. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. , 2008, Neoplasia.
[20] N. Lin,et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.
[21] D. Levine,et al. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission , 2007, Cancer.
[22] S. Narod,et al. Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.
[23] T. Zhao,et al. A Phase II Clinical Trial of Flutamide in the Treatment of Advanced Breast Cancer , 1988, Tumori.
[24] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[25] David Cameron,et al. Identification of molecular apocrine breast tumours by microarray analysis , 2005, Oncogene.
[26] E. Winer,et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[28] A. Naderi,et al. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer , 2011, Breast Cancer Research.
[29] Y. Niu,et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[31] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[32] Huang Jun,et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype , 2014 .
[33] K. Lee,et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Jeff Myers,et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.